OranssiBio specializes in advanced cell and gene therapy solutions, offering a comprehensive range of services tailored to meet the diverse needs of therapeutic development programs. The company employs a variety of innovative platforms, including those for T cells, NK cells, viral vectors, exosomes, and plasmids. Their focus on collaboration ensures that they work closely with clients to create customized solutions that align with specific project requirements. This commitment to precision and innovation positions OranssiBio as a trusted partner in the evolving landscape of cell and gene therapy.

One of the key technologies utilized by OranssiBio is the Adeno-Associated Virus (AAV) platform, recognized for its safety and effectiveness in gene delivery. AAV serves as a versatile viral vector for transporting therapeutic genes into target cells, making it integral to many gene therapy applications. OranssiBio's AAV services are supported by a US/EU compliant facility that adheres to Good Manufacturing Practices (GMP) and includes fully integrated offerings such as process development, quality control, and regulatory support. Their scalable production capabilities, utilizing serum-free suspension processes and automated purification systems, ensure high productivity and quality, facilitating rapid development and delivery of gene therapy products.

China

4188 Canghai Rd., Bldg. C9, Shanghai, China 201206

Oranssibio

Adeno-associated viral vector (AAV)

Oranssibio

Company Details